about
The Impact of Company-Level ART Provision to a Mining Workforce in South Africa: A Cost-Benefit AnalysisPrevention of mother-to-child transmission of HIV: assessing the accuracy of routinely collected data on maternal antiretroviral prophylaxis coverage in Kenya.The impact of antiretroviral therapy on mortality in HIV positive people during tuberculosis treatment: a systematic review and meta-analysis.Spectrum of non-tuberculous mycobacteria identified using standard biochemical testing vs. 16S sequencing.Linking women who test HIV-positive in pregnancy-related services to HIV care and treatment services in Kenya: a mixed methods prospective cohort study.Missed Opportunities for TB Investigation in Primary Care Clinics in South Africa: Experience from the XTEND Trial.Trends in silicosis prevalence and the healthy worker effect among gold miners in South Africa: a prevalence study with follow up of employment status.The natural history of HIV-1 and HIV-2 infections in adults in Africa: a literature reviewIntegrating evidence based medicine into routine clinical practice: seven years' experience at the Hospital for Tropical Diseases, LondonChanging patterns of respiratory disease in HIV positive patients in a referral centre in the United Kingdom between 1986-7 and 1990-1Delays and loss to follow-up before treatment of drug-resistant tuberculosis following implementation of Xpert MTB/RIF in South Africa: A retrospective cohort study.Schistosomiasis in travellers returning from sub-Saharan Africa.Managing drug resistant tuberculosis.Ability of preventive therapy to cure latent Mycobacterium tuberculosis infection in HIV-infected individuals in high-burden settings.Parasitic infections of the lung: a guide for the respiratory physician.Patient attrition between diagnosis with HIV in pregnancy-related services and long-term HIV care and treatment services in Kenya: a retrospective study.HIV infection, tuberculosis and non-tuberculous mycobacteria.Morbidity and mortality in South African gold miners: impact of untreated disease due to human immunodeficiency virus.Screening for tuberculosis prior to isoniazid preventive therapy among HIV-infected gold miners in South Africa.Tuberculosis screening in patients with HIV: An audit against UK national guidelines to assess current practice and the effectiveness of an electronic tuberculosis-screening prompt.Prevalence of vitamin D deficiency in HIV-positive, antiretroviral treatment-naïve patients in a single centre study.Tuberculosis in travellers.A cluster randomised trial to evaluate the effect of optimising TB/HIV integration on patient level outcomes: the "merge" trial protocol.Case reports: acute hookworm infection: an unusual cause of profuse watery diarrhoea in returned travellers.Perceptions and experiences of tuberculosis among African patients attending a tuberculosis clinic in London.Accelerating progress towards tuberculosis elimination: the need for combination treatment and prevention.Factors influencing uptake of HIV care and treatment among children in South Africa - a qualitative study of caregivers and clinic staff.Early risk assessment for viral haemorrhagic fever: experience at the Hospital for Tropical Diseases, London, UK.Natural history and spectrum of disease in adults with HIV/AIDS in Africa.Attitudes to HIV voluntary counselling and testing among mineworkers in South Africa: will availability of antiretroviral therapy encourage testing?Integrated tuberculosis and HIV care in a resource-limited setting: experience from the Martin Preuss centre, Malawi.Spectrum of disease among HIV-infected adults hospitalised in a respiratory medicine unit in Abidjan, Côte d'Ivoire.Tuberculosis among adults starting antiretroviral therapy in South Africa: the need for routine case finding.[Aetiologies of pleural effusions in HIV-infected patients in Abidjan, Côte-d'Ivoire]A Trial of Mass Isoniazid Preventive Therapy for Tuberculosis ControlContribution of reinfection to recurrent tuberculosis in South African gold minersHIV-1 infection and risk of tuberculosis after rifampicin treatmentBritish HIV Association and British Infection Association guidelines for the treatment of opportunistic infection in HIV-seropositive individuals 2011Efficacy of trimethoprim-sulphamethoxazole prophylaxis to decrease morbidity and mortality in HIV-1-infected patients with tuberculosis in Abidjan, Côte d'Ivoire: a randomised controlled trialLiquid vs. solid culture for tuberculosis: performance and cost in a resource-constrained setting
P50
Q28608172-62DBCA1C-68F3-4914-9CAF-8B05446621D7Q34161736-74C68318-3ECC-418C-897F-B3DDB1C9ED32Q34497528-9E47B303-8963-434A-A105-86434D406394Q34507959-C302483F-69C5-42BD-B0E5-09BB0ABF587FQ35124829-80B37313-DB13-4063-B50E-512439BAF02FQ35780201-B41C8C46-D84A-49E0-A487-0524E5C59787Q35873696-BF267CFE-5EFB-4A80-B757-F30E67A302E2Q35882391-6C3D495E-324F-49A8-A8C0-1CD984AB9C89Q35932827-55B27E11-E977-41A6-8F46-655CB8501EC1Q36276362-A485285A-CAB9-4114-8B01-5B09A4820DADQ36286134-92FBAED4-5712-40EE-8F94-A55D8220CB3BQ36599526-4C49804C-C2F7-41F9-9036-07F7F81E538DQ37255657-CE769893-6CBD-4E47-8414-36D194FB340AQ37702101-09A4BC77-6A51-4DB7-AC02-506E54775191Q37794515-0ABF2CC1-AD14-4995-BD14-B3A92CC96098Q37994053-1E4FFBE1-625B-4562-B355-CC81ADBA7417Q38947221-5AC12ACF-7B82-4949-82CA-E96271117E63Q38953092-24D714F6-8E20-4DBD-BA15-4A8D2FACA60FQ38964199-2CD7EC00-F3FE-4382-A969-2858E8EE5082Q39009806-AE20D659-D4F1-434E-90D3-112531DCD443Q39019753-2418F13C-1617-4D96-B67D-E43C7180AA99Q39109711-09EE2ED9-6375-49E4-881D-02E47A0B4551Q39150195-2A4CBA27-C9FE-4F44-B0A7-717FFAC9290AQ39163427-CBCD0124-1906-4F68-BD0F-03411FD37BC6Q39307157-3AFE1535-F41D-47C2-929D-2DD725767B5BQ39390694-362EF86C-29A7-40D5-BFB5-074C11316CDDQ39615464-20D5CF39-FB84-43DE-BB74-E26075F85815Q40483491-57025F63-CDE6-4E2F-8C4C-72EDBB91AD9CQ40910060-648549B0-C9B0-45CC-A112-6C98810B688CQ44012200-11A9F78D-6C90-43FC-A3F6-CD4E761338C8Q46985317-DD801D5E-90F3-4CA8-A537-EAA06E376B19Q50128459-B19501D1-17E5-4719-A29D-B5BDC284988BQ51325568-185455FF-8043-4DE8-B9C9-3BFDCE5863E3Q54119987-63FDDADC-9A57-4A19-9015-D0CA46259767Q56880062-F02DE757-AE02-4D47-93EE-6B4A06B45C18Q57385441-872AA2C6-1E67-448A-899B-1220D6B17D4DQ58028316-8D5950FA-5C05-4E47-A345-C114DF8175E4Q59650717-8D10218E-C611-4FC0-BB2D-42658E07BE91Q64131962-1286ADD3-9085-4FDD-879A-1F7D608AFC15Q84564813-FA681A43-6B2B-4B18-81ED-DD5ECA9F5DE1
P50
description
researcher
@en
wetenschapper
@nl
name
A D Grant
@en
A D Grant
@nl
type
label
A D Grant
@en
A D Grant
@nl
prefLabel
A D Grant
@en
A D Grant
@nl
P106
P31
P496
0000-0002-2437-5195